Visualitzant O - Articles científics per títol

FAIM-L - SIVA-1: Two Modulators of XIAP in Non-Apoptotic Caspase Function

Coccia, Elena; Sole Piñol, Montse; Comella, Joan X (Frontiers Media, 2022-01-10)

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service

Matta, Bruna; Gomes Junior, Renan Gabriel; Mattos, Daniel; Olicio, Renata; Macedo do Nascimento, Caroline; Ferreira, Gerson Moura (Nature Portfolio, 2022-11-03)

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

Turpin, Anthony; Delliaux, Carine; Pauline, PARENT; Chevalier, Hortense; Escudero Iriarte, Carmen; Bonardi, Franck; Querol, Jessica; Herranz Martín, Nicolás; TIAN, TIAN (Springer Nature, 2023-12-07)

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging

Blumberg, Stefano B.; Battiston, Marco; Kakkar, Lebina S.; Lin, Hongxiang; Ianus, Andrada; Grussu, Francesco (Frontiers Media, 2021-11)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Bekaii-Saab, Tanios S; Valle, Juan W; Van Cutsem, Eric; Rimassa, Lorenza; Furuse, Junji; Ioka, Tatsuya; Macarulla Mercadé, Teresa (Future Medicine, 2020-10)

Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC

Nishio, Makoto; Felip Font, Enriqueta; Orlov, Sergey; Park, Keunchil; Yu, Chong-Jen; Tsai, Chun-Ming (Elsevier, 2020-04)

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Yoshino, Takayuki; Di Bartolomeo, Maria; Raghav, Kanwal; Masuishi, Toshiki; Loupakis, Fotios; Kawakami, Hisato; Elez, Elena (Nature Portfolio, 2023-06-07)

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

Tewari, Krishnansu S.; Sill, Michael W.; Birrer, Michael J.; Penson, Richard; Huang, Helen; Moore, David H.; Oaknin Benzaquen, Ana Mazaltob (Elsevier, 2023-04)

Finding MYCure

Beaulieu, Marie-Eve; Soucek, Laura (Taylor and Francis, 2019-06-20)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

Pernas, Sonia; Villagrasa, Patricia; Vivancos Prellezo, Ana; Scaltriti, Maurizio; Rodon Ahnert, Jordi; Burgués, Octavio; Nuciforo, Paolo Giovanni; Antunes de Melo Oliveira, Ana Mafalda (Frontiers Media, 2021-11-04)

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Ameratunga, Malaka; Braña Garcia, Irene; Bono, Petri; Postel-Vinay, Sophie; Plummer, Ruth; Aspegren, John (Springer Nature, 2020-12-08)

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Yap, Timothy A.; Vieito Villar, Maria; Baldini, Capucine; Sepúlveda, Juan Manuel; Kondo, Shunsuke; Simonelli, Matteo (American Association for Cancer Research, 2021-12)

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Salamero García, Olga; Willekens, Christophe; Pérez-Simón, José Antonio; Pigneux, Arnaud; Récher, Christian; Carpio Segura, Cecilia Carmen; Bosch Albareda, Francesc; Montesinos, Pau (American Society of Clinical Oncology, 2020-12-20)

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Piha-Paul, Sarina; Geva, Ravit; Tan, Tira; Lim, Darren Wan-Teck; Hierro Carbó, Cinta; Doi, Toshikiko (BMJ, 2021-08)

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Davis, Elizabeth J; Martín Liberal, Juan Jesús; Kristeleit, Rebecca S; Cho, Daniel; Blagden, Sarah P; Berthold, Dominik; Vieito Villar, Maria (BMJ, 2022-10)

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Boyiadzis, Michael; Desai, Pinkal; Daskalakis, Nikki; Donnellan, William; Ferrante, Lucille; Goldberg, Jenna D.; Salamero García, Olga (Wiley, 2023-03)

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

Narayan, Rupa; Alfonso-Piérola, Ana; Donnellan, William; Abdul-Hay, Maher; Molero , Antonieta; Platzbecker, Uwe (Wiley, 2024-03-18)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

Martín Liberal, Juan Jesús; Hollebecque, Antoine; Jungels, Christiane; Martin-Romano, Patricia; Rodon Ahnert, Jordi; Aftimos, Philippe (Springer Nature, 2020-10)

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Felip Font, Enriqueta; Morgensztern, Daniel; Trigo, José Manuel; Moreno, Victor; Curigliano, Giuseppe; Rutkowski, Piotr (Springer, 2022-04)

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study

Prager, Gerald W; Westphalen, C Benedikt; D'Esquermes, Nathalie; Ferreras, Anabel; Macarulla Mercadé, Teresa; Taieb, Julien; Melisi, Davide (BMJ, 2020-01-20)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

FAIM-L - SIVA-1: Two Modulators of XIAP in Non-Apoptotic Caspase Function

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

Finding MYCure

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

FAIM-L - SIVA-1: Two Modulators of XIAP in Non-Apoptotic Caspase Function ﻿

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service ﻿

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor ﻿

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging ﻿

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements ﻿

Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC ﻿

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer ﻿

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study ﻿

Finding MYCure ﻿

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study ﻿

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours ﻿

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer ﻿

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia ﻿

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas ﻿

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors ﻿

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia ﻿

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome ﻿

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours ﻿

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers ﻿

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

FAIM-L - SIVA-1: Two Modulators of XIAP in Non-Apoptotic Caspase Function

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

Feasibility of Data-Driven, Model-Free Quantitative MRI Protocol Design: Application to Brain and Prostate Diffusion-Relaxation Imaging

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

Finding MYCure

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study